RxDoctor Payments Data

Sloan Rush, MD

Ophthalmology · Amarillo, TXNPI 1356535678

Payments from drug & device makers

$197,171in general payments, 2019–2025

Across 40 payments — averaging $4929.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon Research LLC$177K
  • Rxsight Inc$20K
  • Alcon$301
  • Biotissue Holdings Inc.$68
  • Rayner Intraocular Lenses Limited$47
  • Glaukos Corporation$37
  • plus $70 from 4 others

What the payments were for

  • Consulting fees$7,00092%
  • Speaking & faculty fees$260%
  • Food & beverage$5567%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$197,171 in reported general payments places this provider in the 90th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$624,365
Medicare patients
972
Services billed
4,108

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine32$24,113
Prednisolone Acetate338$15,170
MieboPerfluorohexyloctane/Pf13$13,808
Loteprednol Etabonate26$2,945
Diclofenac Sodium81$1,410
Acyclovir71$1,350
MoxifloxacinMoxifloxacin Hcl40$887
Ofloxacin55$607
ErythromycinErythromycin Base27$296
Dorzolamide Hcl19$268
Latanoprost29$231
Timolol Maleate26$212
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat19$153
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha11$107

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$13$2,94526 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Amarillo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →